Baker Brothers portfolio, Q1 2026

Baker Bros. Advisors · 13F for the quarter ending Mar 31, 2026

For Q1 2026, Baker Bros. Advisors reported $17.4B across 84 US-listed positions, led by INCY (16.6%), ONC (15.0%) and INSM (7.0%). Compared with its filing for Q4 2025, Baker Brothers opened 7 new positions, added to 18, reduced 6 and sold out of 9; 52 positions did not change.

The largest purchase was an addition to PRAX ($201.9M); the largest sale, the sale of the whole position in RARE ($63.8M).

Reported value
$17.4B
Positions
84
In the top 10
73%
Filed
May 15
2026

Key facts

13F portfolio value
$17.4BQ1 2026
Positions
84
Largest holding
INCY 16.6%
New positions
7
Sold out
9
Filed
May 15, 2026

Holdings as of (Q1 2026), filed with the SEC on . Changes are measured against the filing for Dec 31, 2025. Every tracked investor's Q1 2026 13F.

Bought and sold in Q1 2026

Baker Brothers: buys and sells in Q1 2026
StockMoveSharesSizeOf portfolio
Praxis Precision MedicinesPRAX▲ Added 56%+626.71K$201.9M1.16%
Insmed IncINSM▲ Added 13%+828.37K$135.5M0.78%
Grail IncGRAL▲ Added 93%+1.94M$100.4M0.58%
Ultragenyx PharmaceuticalRARE▼ Sold out−2.77M$63.8M0.37%
Immunocore Holdings plcIMCR▼ Reduced 68%−1.59M$47.9M0.27%
Mirum Pharmaceuticals IncMIRM▲ New+445.98K$41.2M0.24%
Terns Pharmaceuticals Incno ticker on file
▼ Sold out−950K$38.4M0.22%
Crinetics Pharmaceuticalsno ticker on file
▲ Added 43%+702.6K$25.5M0.15%
Enliven Therapeutics IncELVN▲ Added 234%+633.79K$24.8M0.14%
BioNTech SEBNTX▼ Reduced 68%−249.18K$22.1M0.13%
BioCryst Pharmaceuticals IncBCRX▼ Sold out−2.82M$22M0.13%
Ventyx Biosciences Incno ticker on file
▼ Sold out−2.35M$21.2M0.12%
Evommune IncEVMN▲ New+847.39K$19.5M0.11%
Ionis Pharmaceuticals IncIONS▲ Added 14%+255.89K$19.2M0.11%
Roivant Sciences LtdROIV▼ Reduced 12%−687.29K$19M0.11%
Aktis Oncology IncAKTS▲ New+996.35K$17.8M0.10%
Generate Biomedicines IncGENB▲ New+1.42M$17.8M0.10%
Nuvalent Incno ticker on file
▼ Sold out−143.94K$14.5M0.08%
Compass Pathways PlcCMPS▲ New+2.34M$13M0.07%
Immatics N.V.IMTX▼ Reduced 9.7%−1.18M$11.6M0.07%
Arrowhead PharmaceuticalsARWR▼ Reduced 8.4%−182.86K$11.5M0.07%
IDEAYA Biosciences IncIDYA▲ Added 9.1%+327.69K$10.9M0.06%
Alumis IncALMS▲ Added 29%+450K$9.9M0.06%
Revolution Medicines IncRVMD▲ Added 1.1%+100K$9.7M0.06%
Abcellera Biologics IncABCL▲ Added 10.0%+2.75M$9.6M0.06%
Tectonic Therapeutic IncTECX▼ Reduced 33%−295.61K$9.1M0.05%
Eikon Therapeutics IncEIKN▲ New+555.56K$5.9M0.03%
Dianthus Therapeutics IncDNTH▲ Added 7.9%+62.41K$5.2M0.03%
Design Therapeutics IncDSGN▲ Added 16%+352.88K$3.8M0.02%
4D Molecular TherapeuticsFDMT▼ Sold out−475.74K$3.6M0.02%
Wave Life Sciences LtdWVE▲ Added 139%+478.58K$3.5M0.02%
CytomX Therapeutics IncCTMX▲ Added 17%+725K$3.4M0.02%
Vir Biotechnology IncVIR▼ Sold out−542.54K$3.3M0.02%
Arcus Biosciences IncRCUS▲ Added 54%+145.62K$3.1M0.02%
Verastem IncVSTM▲ New+584.76K$3.1M0.02%
KALA BIO IncKALA▼ Sold out−1.8M$1M0.01%
Disc Medicine IncIRON▲ Added 3.7%+12.61K$806.1K0.00%
Skye Bioscience IncSKYE▲ Added 8.6%+124.61K$76.6K0.00%
Acrivon Therapeutics IncACRV▼ Sold out−22.81K$55K0.00%
Incyte CorpINCY▲ Added 0.00%+421$39.6K0.00%

Holdings at the quarter's end

Baker Brothers holdings, Q1 2026
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q4 2025
1Incyte CorpINCYHealth Care16.6%$2.9B30.74M$94.128+ qtrs▲ Added 0.00%
2Beone Medicines LtdONC · SPONSORED ADSHealth Care15.0%$2.6B8.8M$296.978+ qtrsNo change
3Insmed IncINSMHealth Care6.97%$1.2B7.42M$163.528+ qtrs▲ Added 13%
4Madrigal Pharmaceuticals IncMDGLHealth Care6.44%$1.1B2.14M$523.478+ qtrsNo change
5Acadia Pharmaceuticals IncACAD—5.48%$954.9M42.9M$22.268+ qtrsNo change
6Revolution Medicines IncRVMDHealth Care5.34%$929.3M9.56M$97.258+ qtrs▲ Added 1.1%
7Celcuity IncCELC—5.19%$903.5M7.92M$114.148+ qtrsNo change
8Kodiak Sciences IncKODHealth Care4.36%$759.3M19.92M$38.128+ qtrsNo change
9Kymera Therapeutics IncKYMRHealth Care4.14%$721.1M8.66M$83.298+ qtrsNo change
10Summit Therapeutics IncSMMTHealth Care3.96%$690M36.39M$18.968+ qtrsNo change
11Praxis Precision MedicinesPRAXHealth Care3.24%$564.9M1.75M$322.198+ qtrs▲ Added 56%
12Rhythm Pharmaceuticals IncRYTMHealth Care2.80%$487.4M5.6M$86.978+ qtrsNo change
13Alkermes PLCALKS · SHSHealth Care2.03%$354M10.01M$35.368+ qtrsNo change
14Grail IncGRALHealth Care1.20%$208.2M4.03M$51.686 qtrs▲ Added 93%
15Edgewise Therapeutics IncEWTXHealth Care1.19%$207.1M6.58M$31.508+ qtrsNo change
16Ionis Pharmaceuticals IncIONSHealth Care0.88%$153.8M2.05M$75.093 qtrs▲ Added 14%
17Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL AHealth Care0.78%$136.1M2.83M$48.158+ qtrsNo change
18Immunovant IncIMVTHealth Care0.78%$135.6M5.46M$24.848+ qtrsNo change
19Roivant Sciences LtdROIV · SHSHealth Care0.77%$134.8M4.87M$27.708+ qtrs▼ Reduced 12%
20IDEAYA Biosciences IncIDYA—0.76%$131.5M3.95M$33.328+ qtrs▲ Added 9.1%
21Arrowhead PharmaceuticalsARWRHealth Care0.72%$124.9M1.99M$62.704 qtrs▼ Reduced 8.4%
22Stoke Therapeutics IncSTOK—0.62%$108.6M3.34M$32.568+ qtrsNo change
23Immatics N.V.IMTX · SHS—0.62%$107.4M10.92M$9.848+ qtrs▼ Reduced 9.7%
24Abcellera Biologics IncABCL—0.61%$105.7M30.28M$3.498+ qtrs▲ Added 10.0%
25Abivax SAABVX · SPONSORED ADSHealth Care0.56%$97.5M875.8K$111.353 qtrsNo change
26
Crinetics Pharmaceuticalsno ticker on file
—0.49%$85.4M2.35M$36.324 qtrs▲ Added 43%
27Replimune Group IncREPL—0.49%$84.5M11.05M$7.658+ qtrsNo change
28
Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031
—0.43%$74.9M30.75M$2.433 qtrs—
29Nurix Therapeutics IncNRIX—0.42%$72.2M4.66M$15.508+ qtrsNo change
30Denali Therapeutics IncDNLI—0.41%$71.6M3.73M$19.208+ qtrsNo change
31Dianthus Therapeutics IncDNTHHealth Care0.41%$71.5M852.16K$83.924 qtrs▲ Added 7.9%
32Monte Rosa Therapeutics IncGLUE—0.41%$71.5M4.35M$16.458+ qtrsNo change
33Structure Therapeutics IncGPCR · SPONSORED ADS—0.40%$69M1.43M$48.207 qtrsNo change
34Entrada Therapeutics IncTRDA—0.37%$64M5.07M$12.628+ qtrsNo change
35Bicycle Therapeutics PlcBCYC · SPONSORED ADS—0.29%$50.5M10.89M$4.648+ qtrsNo change
36Spyre Therapeutics IncSYREHealth Care0.29%$50.4M1M$50.444 qtrsNo change
37Rapport Therapeutics IncRAPP—0.28%$48.4M1.55M$31.294 qtrsNo change
38Alumis IncALMS—0.26%$44.3M2.01M$22.038+ qtrs▲ Added 29%
39Mirum Pharmaceuticals IncMIRMHealth Care0.24%$41.2M445.98K$92.381 qtrNew
40Viridian Therapeutics IncVRDN—0.22%$38.6M1.97M$19.564 qtrsNo change
41Enliven Therapeutics IncELVN—0.20%$35.5M905.19K$39.208+ qtrs▲ Added 234%
42Prelude Therapeutics IncPRLD—0.20%$34.6M10.12M$3.428+ qtrsNo change
43Dbv Technologies S A SponsoredDBVT · SPONSORED ADS—0.18%$30.5M1.46M$20.898+ qtrsNo change
44Design Therapeutics IncDSGN—0.16%$27.5M2.59M$10.648+ qtrs▲ Added 16%
45
Centessa Pharmaceuticals PLCno ticker on file · SPONSORED ADS
—0.15%$26.6M670.75K$39.722 qtrsNo change
46CytomX Therapeutics IncCTMX—0.13%$23.4M4.98M$4.704 qtrs▲ Added 17%
47Jade Biosciences IncJBIO—0.13%$23.1M1.64M$14.052 qtrsNo change
48Disc Medicine IncIRON—0.13%$22.4M349.66K$63.946 qtrs▲ Added 3.7%
49Immunocore Holdings plcIMCR · ADS—0.13%$22.1M734.4K$30.158+ qtrs▼ Reduced 68%
50Xenon Pharmaceuticals IncXENE—0.12%$21.5M370.21K$58.158+ qtrsNo change
51Celldex Therapeutics IncCLDX—0.12%$21.1M665.37K$31.728+ qtrsNo change
52Neurogene IncNGNE—0.12%$20M991.69K$20.168+ qtrsNo change
53Evommune IncEVMN—0.11%$19.5M847.39K$22.991 qtrNew
54Tectonic Therapeutic IncTECX—0.11%$18.8M607.79K$30.915 qtrs▼ Reduced 33%
55Contineum Therapeutics IncCTNM · CL A—0.11%$18.6M1.42M$13.068+ qtrsNo change
56argenx SEARGX · SPONSORED ADRHealth Care0.11%$18.4M25.17K$730.258+ qtrsNo change
57Cerus CorpCERS—0.11%$18.2M10.01M$1.828+ qtrsNo change
58Taysha Gene Therapies IncTSHA—0.10%$17.9M4M$4.478+ qtrsNo change
59Aktis Oncology IncAKTS—0.10%$17.8M996.35K$17.891 qtrNew
60Generate Biomedicines IncGENB—0.10%$17.8M1.42M$12.501 qtrNew
61Sionna Therapeutics IncSION—0.09%$16M400K$40.095 qtrsNo change
62Dyne Therapeutics IncDYN—0.09%$14.7M813.45K$18.132 qtrsNo change
63Xencor IncXNCR—0.08%$13.3M1.1M$12.068+ qtrsNo change
64Compass Pathways PlcCMPS · SPONSORED ADS—0.07%$13M2.34M$5.531 qtrNew
65Relay Therapeutics IncRLAY—0.07%$11.5M1.16M$9.958+ qtrsNo change
66Sera Prognostics IncSERA · CLASS A COM—0.06%$11.2M5.5M$2.038+ qtrsNo change
67BioNTech SEBNTX · SPONSORED ADSHealth Care0.06%$10.6M119.74K$88.886 qtrs▼ Reduced 68%
68Pharvaris N VPHVS—0.06%$10.6M375K$28.253 qtrsNo change
69Arcus Biosciences IncRCUS—0.05%$9M415.62K$21.602 qtrs▲ Added 54%
70Maplight Therapeutics IncMPLT—0.04%$7.4M364.71K$20.332 qtrsNo change
71Absci CorpABSI—0.04%$6.4M2.13M$3.002 qtrsNo change
72Wave Life Sciences LtdWVE · SHS—0.03%$6M822.64K$7.257 qtrs▲ Added 139%
73vTv Therapeutics IncVTVT · CL A—0.03%$5.9M148.31K$39.668+ qtrsNo change
74Eikon Therapeutics IncEIKN—0.03%$5.9M555.56K$10.581 qtrNew
75Protara Therapeutics IncTARA—0.03%$5.1M971.61K$5.218+ qtrsNo change
76Sagimet Biosciences IncSGMT—0.03%$5M953K$5.228+ qtrsNo change
77LB Pharmaceuticals IncLBRX—0.03%$4.9M200K$24.663 qtrsNo change
78Verastem IncVSTM—0.02%$3.1M584.76K$5.301 qtrNew
79TScan Therapeutics IncTCRX—0.02%$2.8M2.78M$1.018+ qtrsNo change
80Skye Bioscience IncSKYE—0.01%$968.1K1.58M$0.61468+ qtrs▲ Added 8.6%
81Sana Biotechnology IncSANA—0.01%$894.2K310.48K$2.888+ qtrsNo change
82Aligos Therapeutics IncALGS—0.00%$617.1K83.06K$7.438+ qtrsNo change
83Tyra Biosciences IncTYRA—0.00%$406.2K10.61K$38.308+ qtrsNo change
84
Surrozen Incno ticker on file · W EXP 8/11/2026
—0.00%$13.3K833.33K$0.01608+ qtrsNo change

By sector

Baker Brothers portfolio by sector, Q1 2026
SectorShare of portfolioValuePositions
Health Care78.9%$13.7B24
No sector on file21.1%$3.7B60

Questions and answers

What did Baker Brothers own in Q1 2026?

Baker Bros. Advisors's 13F for Q1 2026 lists 84 positions worth $17.4B. The largest: INCY (16.6%), ONC (15.0%), INSM (7.0%), MDGL (6.4%), ACAD (5.5%).

What did Baker Brothers buy in Q1 2026?

The largest purchases, by the shares bought at the quarter-end price the filing implies: PRAX (added, $201.9M), INSM (added, $135.5M), GRAL (added, $100.4M), MIRM (new, $41.2M), Crinetics Pharmaceuticals (added, $25.5M), ELVN (added, $24.8M).

What did Baker Brothers sell in Q1 2026?

The largest sales: RARE (sold out, $63.8M), IMCR (reduced, $47.9M), Terns Pharmaceuticals Inc (sold out, $38.4M), BNTX (reduced, $22.1M), BCRX (sold out, $22M), Ventyx Biosciences Inc (sold out, $21.2M).

When was this filing made?

Baker Bros. Advisors filed its 13F for the quarter ending Mar 31, 2026 on May 15, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Baker Brothers portfolio, Q1 2026: Baker Bros. Advisors 13F holdings”, data as of 15 May 2026. https://funkfolio.com/gurus/baker-brothers/2026-q1

Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Mar 31, 2026.

Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Mar 31, 2026, filed May 15, 2026. Changes compare share counts with the filing for Dec 31, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $17.4B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 8 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.